Oramed initiates Phase IIa trials on Type 1 diabetics
Oramed’s Phase IIa trial is focused on assessing the safety and efficacy of its oral insulin capsule on nine Type 1 diabetes patients. The start of this clinical
The US Food and Drug Administration (FDA) has approved an expanded indication for Eli Lilly and Company’s Jaypirca (pirtobrutinib) as a first-line treatment for adults with previously untreated chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL) who do not have a 17p deletion.
These applications include ultra-deep amplicon sequencing for detection of low-frequency mutations in disease associated genes, and the comprehensive identification and quantification of common and rare variants within a